We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Akero Therapeutics, Inc. (AKRO)
Enanta Pharmaceuticals, Inc. (ENTA)
Galectin Therapeutics Inc. (GALT)
Galmed Pharmaceuticals Ltd. (GLMD)
Hepion Pharmaceuticals, Inc. (HEPA)
Ionis Pharmaceuticals, Inc. (IONS)
Inventiva S.A. Sponsored ADR (IVA)
Madrigal Pharmaceuticals, Inc. (MDGL)
Sagimet Biosciences Inc. (SGMT)
Inventiva Phase 2 study for MASH drug meets primary endpoint
Read full article here »